AbbVie’s stock fell despite strong Q4 results. Revenue rose 10% to $16.6 billion, driven by Skyrizi and Rinvoq sales growth. Humira faces biosimilar competition, leading to sales decline. Despite challenges, AbbVie projects 9.5% sales growth in 2026, with $31 billion combined Skyrizi and Rinvoq sales.

Investors are concerned about Humira’s declining sales impact on overall revenue growth. AbbVie seeks new growth drivers like tavapadon for Parkinson’s disease. The company’s dividend track record, increasing for 54 years, makes it a top pick for long-term income seekers.

Stock Advisor lists 10 best stocks to buy, excluding AbbVie. Past recommendations like Netflix and Nvidia had significant returns. Stock Advisor’s total average return is 884%, outperforming the S&P 500. Investors can access the latest top 10 list and join an investing community through Stock Advisor.

Read more at Yahoo Finance: 1 No-Brainer Dividend Stock to Buy on the Dip